Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$28.84 ▲ +0.06
(+0.21%)
MKT CAP: $2.98B • VOL: 2.00M
52W L $20 52W H $38
BEAM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $139.7M | $63.5M | $377.7M |
| YoY Revenue Growth % | +120.0% | -83.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$383.7M | -$415.6M | -$176.5M |
| Operating Margin % | -80.0% | -80.0% | -46.7% |
| Net Income (GAAP) | -$80.0M | -$376.7M | -$132.5M |
| EBITDA (Normalized) | -$371.7M | -$408.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$345.1M | -$347.2M | -$149.2M |
| Capital Expenditures (CapEx) | $14.9M | $8.9M | — |
| Free Cash Flow (FCF) | -$360.0M | -$356.2M | -$149.2M |
| FCF Margin % | -80.0% | -80.0% | -39.5% |
| Return on Invested Capital (ROIC %) | -32.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $294.9M | $282.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.24B | $733.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BEAM.